Leishmaniasis is a chronic disease caused by flagellate protozoa of the genus Leishmania.
It is a global disease, but most cases are seen in South America, the Mediterranean, and …

Leishmaniasis is a global term for cutaneous and visceral anthroponotic and zoonotic
diseases caused by the vector-borne parasites of the genus Leishmania. These diseases …

Leishmaniasis is a tropical disease caused by an intracellular parasite of the genus
Leishmania. The vector of transmission is the sandfly, which deposits one of the 20 disease …

Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …

Introduction: Leishmaniasis is a vector-borne neglected tropical disease which manifests as
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …

Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL). The treatment of VL is …

Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream.
Topical imiquimod stimulates the innate and adaptive immune responses and induces …

The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60
years, treatment of leishmaniasis has centered around pentavalent antimonials (Sb v) …

Cutaneous leishmaniasis has been endemic since decades. Millions of cases are reported
worldwide specially in developing and underdeveloped countries. There are 2 major types …

Estimated worldwide incidence of tegumentary leishmaniasis (cutaneous leishmaniasis [CL]
and mucocutaneous leishmaniasis [MCL]) is over 1.5 million cases per year in 82 countries …